OCTOPOD-IV (NCT06618235) is a first-in-human, multi-centre trial to assess safety, tolerability and preliminary efficacy of THEO-260 in patients with high-grade serous ovarian or endometrioid cancer.

The platinum-resistant ovarian cancer market is expanding due to a growing unmet need, as many patients relapse after first-line platinum therapies, driving demand for novel second- and later-line ...

Ovarian steroid cell tumors are rare, representing less than 0.1% of all ovarian neoplasms. Among the myriad causes of hirsutism, ovarian tumors account for 1% of the reported cases. We present the ...

The platinum-resistant ovarian cancer market is expanding due to a growing unmet need, as many patients relapse after first-line platinum therapies, driving demand for novel second- ...

Department of Radiology, Jinshan Hospital of Fudan University, Shanghai, China Objective: To evaluate the diagnostic efficacy of intravoxel incoherent motion (IVIM) parameters in ovarian stroma ...

1 Virginia Cancer Specialists, Lansdowne, VA, USA. 2 Department of Surgery, Johns Hopkins University, Baltimore, MD, USA. 3 Department of Pathology, Penn State Health ...

Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment paradigms in ovarian cancer. Mirvetuximab soravtansine-gynx (Elahere) ...

High-risk MSCs (yellow) are more abundant in fallopian tubes from patients with STIC lesions (bottom) compared to those without these lesions (top). Researchers at the University of Pittsburgh have ...

Researchers at the University of Pittsburgh have identified a novel trigger of a deadly form of ovarian cancer: a subset of progenitor cells that reside in fallopian tube supportive tissue, or stroma.

High-risk MSCs (yellow) are more abundant in fallopian tubes from patients with STIC lesions (bottom) compared to those without these lesions (top). Credit: Garcia et al. 2025, Cancer Discovery ...